

ARTICLE

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy

Dana Haddad^{1,2}, Nicholas Socci³, Chun-Hao Chen¹, Nanhai G Chen^{4,5}, Qian Zhang⁵, Susanne G Carpenter¹, Arjun Mittra¹, Aladar A Szalay^{2,4,5} and Yuman Fong⁶

Background: Pancreatic cancer is a fatal disease associated with resistance to conventional therapies. This study aimed to determine changes in gene expression patterns associated with infection and susceptibility of pancreatic cancer cells to an oncolytic vaccinia virus, GLV-1h153, carrying the human sodium iodide symporter for deep tissue imaging of virotherapy.

Methods: Replication and susceptibility of pancreatic adenocarcinoma PANC-1 cells to GLV-1h153 was confirmed with replication and cytotoxicity assays. PANC-1 cells were then infected with GLV-1h153 and near-synchronous infection confirmed via flow cytometry of viral-induced green fluorescent protein (GFP) expression. Six and 24 hours after infection, three samples of each time point were harvested, and gene expression patterns assessed using HG-U133A cDNA microarray chips as compared to uninfected control. Differentially expressed genes were identified using Bioconductor LIMMA statistical analysis package. A fold change of 2.0 or above was used as a cutoff, with a *P* value of 0.01. The gene list was then analyzed using Ingenuity Pathways Analysis software.

Results: Differential gene analysis revealed a total of 12,412 up- and 11,065 downregulated genes at 6 and 24 hours postinfection with GLV-1h153 as compared to control. At 6 hours postinfection, a total of 139 genes were either up or downregulated >twofold (false discovery rate < 0.05), of which 124 were mapped by Ingenuity Pathway Analysis (IPA). By 24 hours postinfection, a total of 5,698 genes were identified and 5,563 mapped by IPA. Microarray revealed gene expression changes, with gene networks demonstrating downregulation of processes such as cell death, cell cycle, and DNA repair, and upregulation of infection mechanisms (*P* < 0.01). Six hours after infection, gene changes involved pathways such as HMGB-1, interleukin (IL)-2, IL-6, IL-8, janus kinase/signal transducer and activator of transcription (JAK/STAT), interferon, and ERK 5 signaling (*P* < 0.01). By 24 hours, prominent pathways included P53- and Myc-induced apoptotic processes, pancreatic adenocarcinoma signaling, and phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene homolog 1 (PI3/AKT) pathways.

Conclusions: Our study reveals the ability to assess time-dependent changes in gene expression patterns in pancreatic cancer cells associated with infection and susceptibility to vaccinia viruses. This suggests that molecular assays may be useful to develop safer and more efficacious oncolytic virotherapies and support the idea that these treatments may target pathways implicated in pancreatic cancer resistance to conventional therapies.

Molecular Therapy — Oncolytics (2016) **3**, 16008; doi:10.1038/mto.2016.8; published online 16 March 2016

BACKGROUND

Oncolytic viral therapies have shown such success in preclinical trials as a novel cancer treatment modality that several phase 1 and 2 trials are already underway.¹ We have previously reported on the construction and generation of a novel attenuated replication-competent vaccinia virus (VACV), GLV-1h153, a derivative of parental virus GLV-1h68 engineered to carry the human sodium iodide symporter (hNIS) for the imaging of viral replication

within tumors via enhanced uptake of several radionuclide probes.² The noninvasive tracking of virus delivery may enable clinicians to correlate efficacy and therapy, monitor potential viral toxicity, and possibly provide a more sensitive and specific diagnostic technique to detect tumor origin and, more importantly, presence of metastases.^{3,4} GLV-1h153 facilitated enhanced dose-dependent radiouptake in cell culture and effective replication and killing of pancreatic cancer cells both in cell culture and in animal models. Furthermore,

The last two authors are co-corresponding authors.

¹Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; ²Department of Biochemistry, University of Wuerzburg, Wuerzburg, Bavaria, Germany;

³Bioinformatics Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; ⁴Genelux Corporation, San Diego Science Center, San Diego, California, USA;

⁵Department of Radiation Oncology, University of California, San Diego, California, USA; ⁶Department of Surgery, City of Hope Medical Center, Los Angeles, California, USA.

Correspondence: Yuman Fong (yfong@coh.org) or Aladar A. Szalay (aaszalay@genelux.com)

Received 27 December 2015; accepted 2 February 2016

GLV-1h153 facilitated enhanced uptake in tumors which was readily detected by positron emission tomography.

In this study, we conducted gene expression analysis using cDNA-GeneChip microarray Human Genome U133A (Affymetrix, Santa Clara, CA) to determine changes in gene expression patterns over time associated with infection and susceptibility of pancreatic cancer cells to GLV-1h153. Understanding into the molecular mechanisms associated with sensitivity to GLV-1h153 may enable identification of cancers resistant to viral therapy, thus avoiding undesirable side effects associated with the need for higher doses of viral treatment. Furthermore, knowledge of these mechanisms may be useful to develop safer and more efficacious oncolytic virotherapies.

RESULTS

GLV-1h153 replication was assessed via flow cytometric detection of GFP

GFP expression in cells infected with GLV-1h153 was quantified using flow analysis and was shown to be both time and multiplicity of infection (MOI) dependent. Almost 70% of live cells expressed GFP at an MOI of 5.0 at 24 hours postinfection (Figure 1a). Viral infection, replication, and cell viability were successfully visualized by assessing GFP expression and were time dependent. Phase overlay pictures shows GFP expression as early as 6 hours postinfection with an MOI of 5, with maximal GFP expression after by 24 hours, and cell death and decline of GFP expression by day 2 (Figure 1b). Based on flow cytometry and visualization of GFP expression, we harvested cells after infection with an MOI of 5 at 0, 6, and 24 hours postinfection. A near-synchronous infection rate was achieved without cell death and lysis occurring too early for harvest.

Identification of time-dependent gene-fold changes

After infecting and harvesting our samples, microarray analysis was performed. mRNA from cells were extracted, and using Affymetrix HG-U133A cDNA microarray chips, differentially expressed genes were identified using Bioconductor LIMMA statistical analysis package. A fold change of 2.0 or above was used as a cutoff, with a *P* value of 0.01. At 6 hours postinfection, a total of 129 genes were either up or downregulated greater than twofold (false discovery rate < 0.05), of which 124 were mapped by Ingenuity Pathway Analysis (IPA). By 24 hours postinfection, a total of 5,698 genes were identified and 5,563 mapped by IPA (Figure 2a; complete microarray

data is available in the public Gene Expression Omnibus repository under the accession number GSE48121). The top five genes up- or downregulated at each time point are listed (Table 1). The top five significant molecular and cellular function groups (according to *P* value) with which common genes were involved entailed roles in cell morphology (11 genes, $P = 7.06 \times 10^5$), cellular development (11 genes, $P = 2.34 \times 10^4$), cellular movement (13 genes, $P = 6.09 \times 10^0$), cellular growth and proliferation (16 genes, $P = 6.37 \times 10^4$), and cell-to-cell signaling and interaction (9 genes, $P = 6.49 \times 10^4$) (Supplementary Files S1 and S2). Utilizing hierarchical clustering heat map, time-dependent gene changes are visually illustrated, with genes gradually becoming less downregulated by 6 hours to upregulated by 24 hours, and vice versa when compared to 0 hours postinfection (Figure 2b).

Network analysis

The IPA software system enables systemic analysis of microarray and other data in a biologic context. Our up- or downregulated genes at each time point were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these focus genes were then algorithmically generated based on their interrelationships. Nine major networks were identified by 6 hours, and by 24 hours, more than 25 networks were identified utilizing involved genes at each time point (Figure 3a, Supplementary Files S1). The top network at 6 hours postinfection included genes with functions related to Cell Death and Cellular Development and involved mostly downregulated genes such as *Il8*, *hmx1*, *bcl3*, *BIRC3*, *cxl2*, *IRF1*, *cx3cl1*, *cdkna* (26 genes). At 24 hours post infection, the top network functions involved Gene Expression, Infection Mechanism, and Tumor Morphology and involved up and downregulated genes such as *TP53*, *GSR*, *TRIO*, *HSPA1L*, *PLK2*, *ABL2* (35 genes) (Figure 3b).

Gene function analysis

We then investigated our overall gene list more closely and analyzed these genes in terms of some important gene and cellular functions. These graphs shows some of the functions deemed associated to our genes. All bars above the line on the graph has a *P* value less than 0.05. Statistical significance was based on the ratio of up or downregulated genes in our data set to all genes involved in the pathway. At 6 hours, important and statistically significant gene




Figure 1 Infection of pancreatic cells and flow cytometry analysis. **(a)** Infection of pancreatic cells to show hNIS protein expression by GLV-1h153, PANC-1 cells were mock infected or infected with GLV-1h153 or parental virus GLV-1h68 at MOIs of 0.1, 1.0, and 5.0 and harvested 24 hours after infection. Results reflect an average of three samples with standard error. **(b)** Viral infection, replication, and cell viability were successfully visualized by assessing GFP expression and was time dependent. Phase overlay pictures shows GFP expression as early as 6 hours post infection with an MOI of 5, with maximal GFP expression after by 24 hours, and cell death and decline of GFP expression by 48 hours. Cells are demonstrated at $\times 20$ magnification.




Figure 2 Differential gene analysis and hierarchical clustering chart/heat map. **(a)** Venn diagram demonstrating differentially up and downregulated genes using Bioconductor LIMMA package at a stricter FDR of <0.01 . A total of 12,412 upregulated and 11,065 downregulated genes were identified without FDR restriction. At 6 hours postinfection, a total of 129 genes were either up- or downregulated greater than twofold (FDR <0.01), of which 124 were mapped by IPA. By 24 hours postinfection, a total of 5,698 genes were identified and 5,563 mapped by IPA. Several genes overlapped between each time point analysis, illustrated by the overlapping portions of each circle. **(b)** Heat map looking at differential changes of common genes. For this case, each gene is normalized as a mean expression of zero. Green shows samples with below mean expression and red is above mean expression. Most of the genes represented a downregulation as compared to control by 24 hours. FDR, false discovery rate.

functions included cell death, cell cycle, cell morphology, growth, and development. By 24 hours after infection, cell death was still the top-rated function but also included further functions such as cell expansion and DNA repair and recombination (Figure 4a). Looking at cell death and apoptosis more closely, statistically significant genes at 6 hours involved mainly antiapoptotic pathways, with downregulation of antiapoptotic genes such as BIRC3, and TNF1IP3. By 24 hours, there is shift to modulation of genes involved in proapoptotic mechanisms, such as underexpression of BID, BAX, casp 3, and BAD creating an overall antiapoptotic state (Figure 4b, Supplementary Files S1 and S2).

Pathway analysis

Canonical pathways were then identified and analyzed from the IPA libraries that were most significant to our common gene data set. The significance of the association between the data set and the canonical pathway was measured in two ways: (i) a ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway is displayed and (ii) Fischer's exact test was used to calculate a P value determining the probability that the association between the genes in the dataset and the canonical pathway is explained by chance alone. IPA identified 52 genes eligible for pathways analysis. Top statistically significant canonical pathways included HMGB-1, interferon, IL-6, and JAK/STAT, signaling at 6 hours postinfection, and by 24 hours prominent pathways included PI3/AKT, epidermal growth factor receptor (EGFR), and extracellular signal-regulated kinases/mitogen-activated protein kinases (ERK/MAPK), signaling

pathways ($P < 0.05$; Figure 5b). Some pathways were activated early and became more active by 24 hours, such as the EGFR pathway, an implicated pathway in pancreatic cancer resistance to conventional therapy (Figure 5b)

DISCUSSION

Vaccinia is a broad-spectrum virus known to infect a wide range of cell types.⁵⁻⁷ Conditionally replicating viruses have been gaining increasing attention for their ability to kill tumor cells by oncolysis and apoptosis, and hence, this attenuated strain has shown promise as a selective anticancer agent.⁵ We constructed a new virus which had three nonessential viral genes deleted and replaced with GFP, β -galactosidase, and the hNIS genes, creating GLV-1h153. hNIS is a symporter which facilitated uptake of radioiodine into GLV-1h153-infected cells, therefore enabling imaging of viral replication *in vivo* utilizing deep tissue imaging modalities such as positron emission tomography and single photon emission computed tomography.^{2,8,9} The virus also killed pancreatic cells both in cell culture and in animal models.

However, there remains a need to understand molecular mechanisms related to oncolytic viral infection and sensitivity to treatment. Therefore, this study investigated time-dependent changes in gene expression patterns associated with infection and susceptibility of pancreatic cancer cells to GLV-1h153. Identification and targeting these gene expression changes are needed to avoid side effects associated with higher doses of virus treatment, help develop new strategies to overcome resistance, and identify candidates for clinical trials.

Table 1 Genes up and downregulated in GLV-1h153-infect PANC-1 cells

| Probe ID | Name | Symbol | Fold change | Average FDR |
|----------------------|---|----------|-------------|----------------------------|
| T6/T0 Upregulated | | | | |
| 211123_at | Solute carrier family 5 (sodium iodide symporter), member 5 | SLC5A5 | 1,893.82 | 4.55496 × 10 ⁸ |
| 207046_at | Histone cluster 2, H4a | HIST2H4A | 161.32 | 5.38612 × 10 ⁵ |
| 216796_s_at | AK026847 | AK026847 | 113.89 | 5.08978 × 10 ⁶ |
| 206951_at | Histone cluster 1, H4e | HIST1H4E | 91.54 | 9.22164 × 10 ⁸ |
| 214516_at | Histone cluster 1, H4b | HIST1H4B | 73.95 | 1.03942 × 10 ⁷ |
| T6/T0 downregulated | | | | |
| 201169_s_at | Basic helix-loop-helix domain containing, class B, 2 | BHLHB2 | -4.67 | 0.000984296 |
| 823_at | chemokine (C-X3-C motif) ligand 1 | CX3CL1 | -4.37 | 0.000173528 |
| 203687_at | chemokine (C-X3-C motif) ligand 1 | CX3CL1 | -4.33 | 0.001296406 |
| 213524_s_at | G0/G1 switch 2 | G0S2 | -4.32 | 0.002112328 |
| 210001_s_at | Suppressor of cytokine signaling 1 | SOCS1 | -4.3 | 0.001525627 |
| T24/T0 upregulated | | | | |
| 211123_at | Solute carrier family 5 (sodium iodide symporter), member 5 | SLC5A5 | 4,935.22 | 1.59464 × 10 ⁹ |
| 216796_s_at | AK026847 | AK026847 | 1,314.03 | 2.21339 × 10 ⁸ |
| 117_at | Heat shock 70 kDa protein 6 (HSP70B') | HSPA6 | 1,106.5 | 2.24183 × 10 ⁹ |
| 213418_at | Heat shock 70 kDa protein 6 (HSP70B') | HSPA6 | 355.86 | 2.2579 × 10 ⁸ |
| 207046_at | Histone cluster 2, H4a | HIST2H4A | 315.33 | 5.72591 × 10 ⁷ |
| T24/T0 downregulated | | | | |
| 211506_s_at | Interleukin 8 | IL8 | -140.35 | 3.6625 × 10 ⁶ |
| 202638_s_at | Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor | ICAM1 | -116.46 | 4.02096 × 10 ⁶ |
| 202037_s_at | Secreted frizzled-related protein 1 | SFRP1 | -101.92 | 3.50598 × 10 ¹¹ |
| 205476_at | Chemokine (C-C motif) ligand 20 | CCL20 | -86.1 | 1.08182 × 10 ⁶ |
| 201980_s_at | Ras suppressor protein 1 | RSU1 | -81.93 | 6.84573 × 10 ⁹ |

FDR, false discovery rate.

Mechanisms of oncotherapy are still poorly understood.¹⁰ The proposed theory of anticancer effects appears to be mainly through oncolysis, although other cellular mechanisms such as apoptosis, necrosis, and autophagy, as well as modification to the tumor vasculature and microenvironment, may also play a role. A study by Weibel *et al.* investigated the contribution of the tumor vasculature and host immune response after therapy of breast cancer xenografts with GLV-1h68, the parent virus of GLV-1h53, and found that VACV-mediated oncolysis was the primary mechanism of tumor shrinkage in the late regression phase with neither the destruction of the tumor vasculature nor the massive VACV-mediated intratumoral inflammation being a prerequisite for tumor regression.¹¹ Response of several cancer cell lines to GLV-1h68 was also investigated by Ascierio *et al.* and showed highly heterogeneous permissivity to VACV infection among the cell lines, but no clear transcriptional pattern could be identified as predictor, suggesting multifactorial basis for permissivity to viral infection.¹² Time and MOI also appear to be important in the effectiveness of viral infection and treatment in a study by Oberg *et al.*¹³ utilizing smallpox and peripheral blood cells from human subjects. They determined that the optimal time

to assess the largest amounts of gene changes was at an MOI of 0.5 PFU/cell, and at 18 hours postinfection. It has been recently shown that GFP-marker gene expression correlated with viral copy number in several cell lines, and we thus harvested infected and control pancreatic cells at a maximum of 24 hours postinfection, as determined by maximal GFP expression.¹¹

It is well known that VACV infection causes significant alterations in cell function and metabolism and interferes with host cell DNA and RNA expression.¹⁴ Our differential gene analysis revealed a total of 12,412 up- and 11,065 downregulated genes at 6 and 24 hours postinfection with GLV-1h153 as compared to control. The top network at 6 hours postinfection included genes with functions related to cell death and cellular development and involved mostly downregulation of genes such as *IL-8*, *hmx1*, *bcl3*, *BIRC3*, *cxcl2*, *IRF1*, *cx3cl1*, *cdkna*. At 24 hours postinfection, the top network functions involved gene expression, infection mechanism, and tumor morphology and involved up- and downregulated genes such as *TP53*, *GSR*, *TRIO*, *HSPA1L*, *PLK2*, *ABL2*. Looking at cell death and apoptosis more closely, it was interesting that at 6 hours, the focus is on genes involved in antiapoptotic pathways, with downregulation of antiapoptotic genes





Figure 4 Gene function analysis. **(a)** Graph showing top cellular functions at 6 and 24 hours post infection. Bars above the line are statistically significant ($P < 0.05$). **(b)** Closer look at cell death showing important genes at 6 hours (left) mainly reflecting antiapoptotic genes, important genes by 24 hours (right) mainly reflecting proapoptotic genes. Red colored genes are overexpressed as compared to parental line; green are underexpressed.

such as *BIRC3*, and *TNF1IP3*. By 24 hours, there is shift to modulation of genes involved in proapoptotic mechanisms, such as underexpression of *BID*, *BAX*, *casp 3*, and *BAD* creating an overall antiapoptotic state. Antiapoptotic mechanisms early in infection may facilitate enhanced viral replication and possibly increased therapeutic efficacy, and several other studies have shown VACV's ability to inhibit apoptosis.^{15,16} In a recent study assessing the permissivity of cell lines to GLV-1h68, *casp3* was initially downregulated, again suggesting that antiapoptosis may help facilitate viral replication.¹¹

There is limited data on specific genes found to be associated with VACV infection, and none looking at pancreatic adenocarcinoma specifically.^{13,17–20} For example, Guerra *et al.* identified upregulation of genes in two clusters containing 20 immune response genes at 2, 6, and 16 hours postinfection in Human HeLa cells in response to modified vaccinia virus Ankara.¹⁹ Some of the key immune response genes belonging to these two clusters, including IL-1A, IL-6, IL-8, and components of signal transduction pathways, such as NFKB2, were identified in our study. Agrawal *et al.* found that vaccinia infection



of dendritic cells induced the secretion of IL-6 and TNF- α , which in turn stimulated IFN- γ secretion from T cells, also upregulated in our study.²¹

We then investigated the involvement of these genes in known cell signaling pathways. Our analysis showed several statistically significant pathways including HMGB-1, IFN, IL-6, and JAK/STAT signaling at 6 hours postinfection, and by 24 hours, prominent pathways included PI3/AKT, EGFR, and ERK/MAPK, signaling pathways. Overexpression of EGFR has been implicated in pancreatic carcinoma aggressiveness and resistance to chemo- and radiation therapy.^{22,23} In a recent study by Morgan *et al.*²⁴, EGFR inhibitors cetuximab and erlotinib was used in combination with gemcitabine for enhanced efficacy against pancreatic cancer. This pathway was significantly modulated by 24 hours after infection with GLV-1h153 in our study, with downregulation of the EGFR receptor, potentially mimicking effects of EGFR inhibitors.

These pathways were also involved in several studies investigating the parent virus of GLV-1h153, GLV-1h68 mostly in tumor xenografts. Worschech *et al.* demonstrated several pathways also common in our study including interferon, IL-6, JAK/STAT, PTEN, and ERK/MAPK signaling.²⁵ Only purine metabolism was a common pathway with Reinboth *et al.*'s study.²⁶ Like Worschech *et al.*, most of our postinfection cellular gene changes reflected a downregulation and shut down of cellular metabolism.²⁵ It is difficult to directly compare changes in gene expression due to RNA isolation from tissue rather than cells, adding the variable of the host immune response and gene expression changes which cannot be assessed in cell culture.

Moreover, attenuation of our virus, GLV-1h153, also likely has an important impact on results demonstrated. GLV-1h153 is a derivative of GLV-1h68, which in turn was derived from wild-type LIPV virus.²⁷ Like GLV-1h153, GLV-1h68 carries three separate insertions in the F14.5L, J2R (TK), and A56R (hemagglutinin) loci of LIPV genome. Zhang *et al.* demonstrated that gene insertions in GLV-1h68 greatly reduced the replication of GLV-1h68 in normal mouse cells, whereas the replication of GLV-1h68 in tumor cells was not detrimentally affected. Furthermore, *i.v.* injection of GLV-1h68 into nude mice with human breast tumor xenografts showed enhanced preference for colonization of tumors when compared with wt LIPV and WR strains, leading to restricted distribution of GLV-1h68 mostly to tumors but not to other organs and therefore resulted in less toxicity and extended survival of tumor-bearing nude mice.

In addition, another paper demonstrated via experiments using wild-type single, double, and triple mutant LIPV viruses that infection and replication of LIPV mutant viruses were not very different from those of wt LIPV, suggesting that the single, double, or triple insertions within the LIPV genome did not detrimentally affect the entry and replication of the virus in tumor cells.²⁸ In normal cells, however, the replication capacity of LIPV mutant viruses was greatly reduced or diminished compared with its wt strain. In addition, virus replication efficiency increased with removal of each of the expression cassettes F14.5L, J2R (TK), and A56R. The increase in virus replication efficiency was also shown to be proportionate to the strength of removed VACV promoters linked to foreign genes, and replication efficiency of the new VACV strains *in vivo* paralleled their cytotoxicity in cell cultures. The authors therefore concluded that replication efficiency of oncolytic VACV in cell cultures can predict the virulence and therapeutic efficacy in nude mice, demonstrating the importance of *in vitro* experiments for further understanding of possible viral interactions *in vivo*.

However, Zhang *et al.* demonstrated via Affymetrix mouse arrays and experiments with breast tumor xenografts at 3 and 6

weeks post viral treatment with GLV-1h68 that genes denoting infiltration and activation of immune cells were strongly detected, which are expressed on activated T cells, natural killer cells, macrophages, granulocytes, and dendritic cells and associated with leukocyte activation and natural killer cytolytic function, suggesting a mouse-related immune response is part of the process leading to breast tumor regression. Preferential activation of proinflammatory transcripts, such as chemokine ligands, IL, and chemokine receptors, as well as a panel of IFN-stimulated genes was also seen. This highlights the importance of applying molecular methodologies *in vivo* in a tumor microenvironment that is as close to clinical application as possible, as it is likely that the innate and adaptive immune responses will also play a role in the way cells behave in response to infection to GLV-1h153. However, prior to conducting such experiments, it would be important to start with a more simplistic approach in cell culture, in order to be in a position to better understand more complex and intertwined gene expression changes and interactions.

Several databases investigating genes associated with poxvirus infection have been established, such as the virus pathogen database and analysis resource (ViPR),⁵ the poxvirus bioinformatics resource center,⁶ the poxvirus proteomics database,⁷ as well as literature addressing detection of and identification of different strains of orthopoxvirus.^{1,29–32} Although these databases were aimed mainly at the risk of bioterrorism or possible virus pandemic, information from these databases may be crucial to better understand virus behavior for oncotherapy.

In summary, this study reveals the ability to assess time-dependent changes of gene expression patterns in pancreatic cancer cells associated with infection and susceptibility to vaccinia viruses. Our study suggests that molecular assays may be useful to develop safer and more efficacious oncolytic viral therapies and that oncolytic viral treatments may target pathways implicated in pancreatic cancer resistance to conventional therapies.

However, we do recognize limitations of our study. Further work is needed to characterize the role of individual genes and pathways in viral therapy susceptibility and possible resistance, and to confirm these genes on a protein and translational level. Moreover, these experiments were conducted in cellular culture, and further work is necessary to establish how pancreatic cancer cells may behave in a biological model, possibly with an intact innate and adaptive immunity in place. This investigation provides a list of genes and pathways for further detailed studies and provides a framework for the observation of possible cellular events, in addition to potential biological and molecular targets to overcome oncolytic viral resistance.

MATERIALS AND METHODS

Virus and cell culture

African green monkey kidney fibroblast CV-1 cells and human pancreatic ductal carcinoma PANC-1 cells were purchased from American Type Culture Collection (Manassas, VA) and were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% antibiotic-antimycotic solution (Mediatech, Herndon, VA) and 10% fetal bovine serum (Mediatech) at 37 °C under 5% CO₂. GLV-1h68 was derived from VACV LIPV, as described previously.²⁷ GLV-1h153 was derived from GLV-1h68, as also previously described.²⁷

Flow cytometry

Cells were seeded on six-well plates at 5 × 10⁵ cells per well. Wells were then infected at multiplicities of infection (MOIs) of 0, 0.01, 1.0, and 5, and cells then harvested at 6 and 24 hours postinfection by trypsinizing and washing with phosphate-buffered saline. GFP expression was analyzed via a Becton-Dickinson FACSscan Plus cytometer (Becton-Dickinson, San Jose, CA).

Analysis was performed using CellQuest software (Becton-Dickinson). Three samples were performed at each time point and averaged.

Preparation of RNA for microarray

Total mRNA preparation was performed in six-well culture plates. Cells were plated at 5×10^5 cells per well and infected with GLV-1h153 at an MOI of 5.0. Zero, 6, and 24 hours postinfection, three samples of at each time point were harvested and lysis performed directly using RNeasy mini kit protocol (Qiagen, Valencia, CA). The mRNA samples were measured by spectrophotometer for proof of purity and hybridized to HG-U133A cDNA microarray chips (AffymetrixInc, Santa Clara, CA) by the genomic core laboratory at Memorial Sloan-Kettering Cancer Center.

Microarray analysis

The HG-U133A cDNA microarray chip images were scanned and processed to CEL files using the standard GCOS analysis suite (AffymetrixInc). CEL files were then normalized and processed to signal intensities using the gcRMA algorithm from the Bioconductor library for the R statistical programming system. All subsequent analysis was done on the log (base 2) transformed data. To find differentially expressed genes a moderated *t*-test was used as implemented in the Bioconductor LIMMA package. To control for multiple testing the false discovery rate method was used with a cutoff of 0.05.

CONFLICT OF INTEREST

N.C., Q.Z., and A.Z. are affiliated with Genelux Corporation. No competing financial interests exist for D.H., C-H.C., N.S., S.C., A. M. and Y.F.

ACKNOWLEDGMENTS

We acknowledge the support of William H. and Alice Goodwin and the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the Memorial Sloan-Kettering Cancer Center core facility for expertise with microarray harvest and analysis.

N.S. was instrumental in study design and statistical gene analysis. C.C. contributed to study design and assisted in *in vitro* studies. N.C. constructed GLV-1h153. Q.Z. was instrumental in hNIS gene construction and viral sequencing. S.C. contributed to the study design and assisted in *in vitro* studies. A.M. contributed to the cytotoxicity and flow cytometry assays. A.Z. is the co-corresponding author and was critical to study design and completion. Y.F. is the corresponding author of this paper and was critical to study design and completion. All authors read and approved the final manuscript.

REFERENCES

1. National Institute of Health. Clinical trials. www.clinicaltrials.gov. Accessed March 2015.
2. Haddad, D, Chen, NG, Zhang, Q, Chen, CH, Yu, YA, Gonzalez, L *et al.* (2011). Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. *J Transl Med* **9**: 36.
3. Serganova, I and Blasberg, R (2005). Reporter gene imaging: potential impact on therapy. *Nucl Med Biol* **32**: 763–780.
4. Serganova, I, Ponomarev, V and Blasberg, R (2007). Human reporter genes: potential use in clinical studies. *Nucl Med Biol* **34**: 791–807.
5. Zhang, Q, Yu, YA, Wang, E, Chen, N, Danner, RL, Munson, PJ *et al.* (2007). Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. *Cancer Res* **67**: 10038–10046.
6. Haddad, D, Chen, CH, Carlin, S, Silberhumer, G, Chen, NG, Zhang, Q *et al.* (2012). Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter. *PLoS ONE* **7**: e41647.
7. Haddad, D, Zanzonico, PB, Carlin, S, Chen, CH, Chen, NG, Zhang, Q *et al.* (2012). A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer. *J Nucl Med* **53**: 1933–1942.
8. Monsurro, V, Beghelli, S, Wang, R, Barbi, S, Coin, S, Di Pasquale, G *et al.* (2010). Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. *J Transl Med* **8**: 10.
9. Ascierto, ML, Worschech, A, Yu, Z, Adams, S, Reinboth, J, Chen, NG *et al.* (2011). Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. *BMC Cancer* **11**: 451.
10. Weibel, S, Raab, V, Yu, YA, Worschech, A, Wang, E, Marincola, FM *et al.* (2011). Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. *BMC Cancer* **11**: 68.

11. Oberg, AL, Dhiman, N, Grill, DE, Ryan, JE, Kennedy, RB and Poland, GA (2011). Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arrays. *J Immunol Methods* **366**: 69–78.
12. Moss, B. *Poxviridae: The Viruses and their Replication*. Philadelphia: Lipincott Williams & Wilkins; 2007.
13. Maluquer de Motes, C, Cooray, S, Ren, H, Almeida, GM, McGourty, K, Bahar, MW *et al.* (2011). Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. *PLoS Pathog* **7**: e1002430.
14. Cooray, S, Bahar, MW, Abrescia, NG, McVey, CE, Bartlett, NW, Chen, RA *et al.* (2007). Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. *J Gen Virol* **88**(Pt 6): 1656–1666.
15. Scherer, CA, Magness, CL, Steiger, KV, Poitinger, ND, Caputo, CM, Miner, DG *et al.* (2007). Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. *Vaccine* **25**: 6458–6473.
16. Guerra, S, López-Fernández, LA, Conde, R, Pascual-Montano, A, Harshman, K and Esteban, M (2004). Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. *J Virol* **78**: 5820–5834.
17. Guerra, S, López-Fernández, LA, Pascual-Montano, A, Muñoz, M, Harshman, K and Esteban, M (2003). Cellular gene expression survey of vaccinia virus infection of human HeLa cells. *J Virol* **77**: 6493–6506.
18. Assarsson, E, Greenbaum, JA, Sundström, M, Schaffer, L, Hammond, JA, Pasquetto, V *et al.* (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. *Proc Natl Acad Sci USA* **105**: 2140–2145.
19. Agrawal, S, Gupta, S and Agrawal, A (2009). Vaccinia virus proteins activate human dendritic cells to induce T cell responses *in vitro*. *Vaccine* **27**: 88–92.
20. Buchsbaum, DJ, Bonner, JA, Grizzle, WE, Stackhouse, MA, Carpenter, M, Hicklin, DJ *et al.* (2002). Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. *Int J Radiat Oncol Biol Phys* **54**: 1180–1193.
21. Burris, H 3rd and Rocha-Lima, C (2008). New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. *Oncologist* **13**: 289–298.
22. Morgan, MA, Parsels, LA, Kollar, LE, Normolle, DP, Maybaum, J and Lawrence, TS (2008). The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. *Clin Cancer Res* **14**: 5142–5149.
23. Worschech, A, Chen, N, Yu, YA, Zhang, Q, Pos, Z, Weibel, S *et al.* (2009). Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. *BMC Genomics* **10**: 301.
24. Reinboth, J, Ascierto, ML, Chen, NG, Zhang, Q, Yu, YA, Aguilar, RJ *et al.* (2012). Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. *Hum Gene Ther Methods* **23**: 285–296.
25. Chen, NG, Yu, YA, Zhang, Q and Szalay, AA (2011). Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice. *J Transl Med* **9**: 164.
26. Pickett, BE, Sadat, EL, Zhang, Y, Noronha, JM, Squires, RB, Hunt, V *et al.* (2012). ViPR: an open bioinformatics database and analysis resource for virology research. *Nucleic Acids Res* **40(Database issue)**: D593–598.
27. Lefkowitz, EJ, Upton, C, Changayil, SS, Buck, C, Traktman, P and Buller, RM (2005). Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. *Nucleic Acids Res* **33(Database issue)**: D3111–D3116.
28. Randall, AZ, Baldi, P and Villarreal, LP (2004). Structural proteomics of the poxvirus family. *Artif Intell Med* **31**: 105–115.
29. Yutin, N, Wolf, YI, Raouf, D and Koonin, EV (2009). Eukaryotic large nucleocytoplasmic DNA viruses: clusters of orthologous genes and reconstruction of viral genome evolution. *Virology* **6**: 223.
30. Rubins, KH, Hensley, LE, Bell, GW, Wang, C, Lefkowitz, EJ, Brown, PO *et al.* (2008). Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. *PLoS ONE* **3**: e2628.
31. Wenli, M, Yan, W, Hongmin, W and Wenling, Z (2004). An oligonucleotide microarray for the detection of vaccinia virus. *Br J Biomed Sci* **61**: 142–145.
32. Da Silva, M and Upton, C (2012). Bioinformatics for analysis of poxvirus genomes. *Methods Mol Biol* **890**: 233–258.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies this paper on the *Molecular Therapy—Oncolytics* website (<http://www.nature.com/mto>)